Mizuho analyst Uy Ear lowered the firm’s price target on uniQure (QURE) to $33 from $60 and keeps an Outperform rating on the shares after lowering the firm’s view of the probability of success and pushing out its expected launch year for AMT-130 by one year following the company announcing that the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 for Huntington’s disease are currently unlikely to provide the primary evidence to support a Biologics License Application.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- These 3 Under-the-Radar Stocks Have Triple-Digit Upside Potential – 12/5/2025
- Midday Fly By: Meta to slash metaverse spending, Salesforce posts Q3 beat
- Video: Salesforce rises, Snowflake dips after quarterly reports
- uniQure Faces Setback in Gene Therapy Approval
- uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA